Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) General Counsel Patrick O’brien sold 14,625 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $60.12, for a total transaction of $879,255.00. Following the sale, the general counsel now directly owns 267,406 shares in the company, valued at $16,076,448.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ:ARWR traded down $1.60 during mid-day trading on Friday, hitting $44.61. The stock had a trading volume of 2,249,708 shares, compared to its average volume of 1,911,396. Arrowhead Pharmaceuticals Inc has a twelve month low of $12.72 and a twelve month high of $73.72. The stock has a 50-day simple moving average of $61.53 and a two-hundred day simple moving average of $42.34. The company has a market capitalization of $4.55 billion, a PE ratio of 64.65 and a beta of 1.97.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.03). The company had revenue of $43.29 million for the quarter, compared to analyst estimates of $36.97 million. Arrowhead Pharmaceuticals had a return on equity of 32.30% and a net margin of 40.27%. As a group, equities analysts anticipate that Arrowhead Pharmaceuticals Inc will post -0.16 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Global Retirement Partners LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $44,000. Nisa Investment Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 96.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 500 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $34,000. NEXT Financial Group Inc acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $139,000. Finally, Moneta Group Investment Advisors LLC purchased a new position in Arrowhead Pharmaceuticals in the 2nd quarter valued at $368,000. 70.33% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have recently commented on ARWR shares. Leerink Swann assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. They issued an “underperform” rating and a $32.00 target price for the company. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price objective (up from $24.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 19th. Robert W. Baird upgraded shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $39.00 to $70.00 in a research report on Monday, November 25th. S&P Equity Research restated a “buy” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 26th. Finally, Oppenheimer began coverage on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. They set a “hold” rating for the company. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $61.14.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Recommended Story: Bid-Ask Spread
Receive News & Ratings for Arrowhead Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
